Access

Article


Nature Medicine 11, 191 - 198 (2005)
Published online: 30 January 2005 | doi:10.1038/nm1185

IKK-bold beta links inflammation to obesity-induced insulin resistance

Melek C Arkan1, Andrea L Hevener2, Florian R Greten1, Shin Maeda1, Zhi-Wei Li1,3, Jeffrey M Long4, Anthony Wynshaw-Boris4, Giuseppe Poli5, Jerrold Olefsky2 & Michael Karin1


Inflammation may underlie the metabolic disorders of insulin resistance and type 2 diabetes. IkappaB kinase beta (IKK-beta, encoded by Ikbkb) is a central coordinator of inflammatory responses through activation of NF-kappaB. To understand the role of IKK-beta in insulin resistance, we used mice lacking this enzyme in hepatocytes (IkbkbDeltahep) or myeloid cells (IkbkbDeltamye). IkbkbDeltahep mice retain liver insulin responsiveness, but develop insulin resistance in muscle and fat in response to high fat diet, obesity or aging. In contrast, IkbkbDeltamye mice retain global insulin sensitivity and are protected from insulin resistance. Thus, IKK-beta acts locally in liver and systemically in myeloid cells, where NF-kappaB activation induces inflammatory mediators that cause insulin resistance. These findings demonstrate the importance of liver cell IKK-beta in hepatic insulin resistance and the central role of myeloid cells in development of systemic insulin resistance. We suggest that inhibition of IKK-beta, especially in myeloid cells, may be used to treat insulin resistance.


$rb.Type.Code